<DOC>
	<DOCNO>NCT01546051</DOCNO>
	<brief_summary>This study evaluate safety , tolerability pharmacokinetics BCI-838 , metabolite BCI-632 several new pro-drugs healthy male subject .</brief_summary>
	<brief_title>A Study BCI-838 Several BCI-632 Prodrugs Healthy Volunteers</brief_title>
	<detailed_description>The first phase study evaluate safety tolerability BCI-838 follow oral administration single dose BCI-838 healthy male subject . The pharmacokinetics BCI-838 metabolite BCI-632 follow single ascend dos BCI-838 evaluate , effect food pharmacokinetics BCI-838 metabolite follow single oral dos BCI-838 healthy male subject . The second phase study evaluate compare relative bioavailability PK metabolite BCI-632 follow single oral administration several new pro-drug candidate healthy male subject .</detailed_description>
	<criteria>Adult male healthy volunteer , 1855 year age Body Mass Index ( BMI ) 18.0 30.0 kg/m2 inclusive Good general health determine medical history physical examination clinically significant medical finding clinically relevant medical surgical history acute ongoing condition within past 30 day Able participate willing give write informed consent comply study restriction Clinically significant medical abnormality , chronic disease history presence significant pulmonary , gastrointestinal , metabolic , cardiac , hepatic , renal neurological disorder History current use alcohol abuse drug addiction Participation drug study within 60 day prior drug administration . Participation 3 drug study 10 month precede start study Donation blood loss 50 mL blood within 60 day prior first drug administration . Donation 1.5 liter blood 10 month precede start study Illness within 5 day prior drug administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>metabotropic glutamate receptor 2 3</keyword>
	<keyword>antagonist</keyword>
	<keyword>mGluR</keyword>
	<keyword>ketamine</keyword>
	<keyword>BDNF</keyword>
	<keyword>Depression</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Mood Disorder</keyword>
	<keyword>Treatment Resistant Depression</keyword>
	<keyword>Phase 1 safety , tolerability pharmacokinetics study</keyword>
</DOC>